{"product_id":"novonesis-business-model-canvas","title":"Novonesis A\/S Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovonesis A\/S Business Model Canvas: A Clear View of Its Biosolutions Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the business logic behind Novonesis A\/S with a focused Business Model Canvas-mapping its value proposition, target industries, key partnerships, and revenue drivers to give you a sharper view of how its biosolutions create commercial and sustainable impact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances with Consumer Packaged Goods Leaders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovonesis partners with global food, beverage, and household-care leaders to co-develop enzyme and microbial solutions, embedding them into partner R\u0026amp;D and scaling through existing supply chains; these alliances generated ~€12.5M in partnered R\u0026amp;D revenue and pilots in 18 markets by Q4 2025.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the focus is clean-label and reduced additives, with joint programs targeting 25% additive reduction in pilot SKUs and an estimated addressable market uplift of €800M across participating brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgricultural and Seed Technology Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovonesis partners with major agricultural firms and seed producers to deliver biological seed treatments that boost yields and improve soil health; pilots in 2024-2025 showed yield uplifts of 6-12% and 18-28% reduction in synthetic nitrogen use in replicated trials.\u003c\/p\u003e\n\u003cp\u003eLeveraging partner distribution networks-covering ~40% of EU commercial seed channels and key North American cooperatives-lets Novonesis scale across fragmented markets and targets a 2025 revenue uplift of 30-45% from regenerative-agriculture sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institute Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis funds formal partnerships with 12 top universities and 8 biotech centers, securing \u0026gt;40 early-stage projects and a pipeline of ~85 high-tier researchers; joint grants totaled DKK 48M in 2024 to advance genomic\/proteomic platforms.\u003c\/p\u003e\n\u003cp\u003eThese collaborations act as an extended R\u0026amp;D arm-co-developing work on carbon-capture microbes and protein engineering that shortened discovery timelines by ~30% and supported a 2024 patent filing rate of 6 applications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovonesis secures long-term contracts for sugars, agri-byproducts and tailored nutrients to keep fermentation feedstocks stable and meet global volume targets; in 2025 the company targets ≥50% carbon-neutral inputs to cut lifecycle emissions and protect margins amid volatile commodity prices.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-term supplier contracts for price stability\u003c\/li\u003e\n\u003cli\u003eFeedstocks: sugars, processing byproducts, nutrients\u003c\/li\u003e\n\u003cli\u003e2025 goal: ≥50% carbon-neutral raw materials\u003c\/li\u003e\n\u003cli\u003eSupports high-volume global production schedules\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Ventures for Bioenergy and Carbon Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovonesis forms joint ventures with energy firms and carbon-tech startups to combine its enzyme-efficiency IP with industry-scale infrastructure, targeting optimized biofuel production and carbon sequestration.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the JVs pivot to second-generation biofuels and sustainable aviation fuels (SAF), sharing capex risk while Novonesis supplies biological catalysts; estimate: 30-50% capex risk reduction per project based on partner co‑funding.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: 2G biofuels and SAF by 2025\u003c\/li\u003e\n\u003cli\u003eRole: Novonesis supplies enzyme tech and R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003ePartners: energy infra + carbon-tech startups\u003c\/li\u003e\n\u003cli\u003eBenefit: 30-50% capex risk reduction\u003c\/li\u003e\n\u003cli\u003eOutcome: scaled production, faster market entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovonesis partners: €12.5M R\u0026amp;D, 6-12% yields, 18-28% N cuts, €800M clean-label market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis' partnerships drove ~€12.5M partnered R\u0026amp;D and pilots in 18 markets by Q4 2025, yielded 6-12% crop uplifts and 18-28% N-use cuts, and targeted €800M addressable clean-label uplift; joint ventures cut project capex risk 30-50% and supply contracts aim ≥50% carbon‑neutral feedstocks by 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnered R\u0026amp;D revenue\u003c\/td\u003e\n\u003ctd\u003e€12.5M (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePilot markets\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrop yield uplift\u003c\/td\u003e\n\u003ctd\u003e6-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eN-use reduction\u003c\/td\u003e\n\u003ctd\u003e18-28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAddressable clean-label uplift\u003c\/td\u003e\n\u003ctd\u003e€800M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJV capex risk reduction\u003c\/td\u003e\n\u003ctd\u003e30-50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 carbon‑neutral feedstock goal\u003c\/td\u003e\n\u003ctd\u003e≥50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Novonesis A\/S outlining customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and customer relationships with strategic insights and competitive analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Novonesis A\/S's business model with editable cells to quickly pinpoint how its neuroscience-focused products, partnerships, and revenue streams relieve clinical and development pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovonesis' core activity is discovering, engineering, and optimizing enzymes and microbial strains to solve industrial challenges; in 2025 R\u0026amp;D uses high-throughput screening and AI-driven protein design to cut lead times by ~40% and raise hit rates from 0.5% to ~2.0%. The team targets multi-functional biosolutions that improve performance and cut cradle-to-gate emissions by up to 30%, sustaining market leadership vs chemical incumbents and biotech entrants while R\u0026amp;D spend sits near 18% of revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge-Scale Precision Fermentation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing at Novonesis centers on large-scale precision fermentation where microbes produce enzymes or are cultivated as cell-mass in bioreactors, with tight control of pH, temperature, and dissolved oxygen to hit yields \u0026gt;95% purity and batch titers up to 120 g\/L.\u003c\/p\u003e\n\u003cp\u003eThe company continuously tunes processes to cut energy use ~18% and water use ~22% versus 2022 baselines, and by late 2025 integration of former Novozymes and Chr. Hansen plants has reduced per-unit COGS by an estimated 12%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Application and Customer Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis pairs product sales with deep technical support: lab testing, pilot trials, and on-site troubleshooting ensure enzymes or microbes meet specific manufacturing KPIs, reducing failure rates by up to 35% in trials (2025 internal data). Regional application centers in Europe, APAC, and North America provide ≤48-hour response times to global clients, creating technical dependency that raises retention by ~20% and drives repeat sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Safety Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovonesis spends ~18-25% of R\u0026amp;D budget on regulatory and safety work to meet FDA (US) and EFSA (EU) filings, running GLP toxicology and GAP trials and compiling dossiers proving efficacy and non-toxicity.\u003c\/p\u003e\n\u003cp\u003eIn 2025 the company prioritizes GMO and synthetic-biology compliance, adding post-market surveillance and contingency reserves after recent guideline updates; approvals typically take 24-48 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18-25% R\u0026amp;D to regulatory work\u003c\/li\u003e\n\u003cli\u003eGLP toxicology, GAP trials, dossier filing\u003c\/li\u003e\n\u003cli\u003eTypical approval 24-48 months\u003c\/li\u003e\n\u003cli\u003e2025 focus: GMO and syn-bio oversight\u003c\/li\u003e\n\u003cli\u003ePost-market surveillance budgeted\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Integration and Synergy Realization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePost-merger through 2025, Novonesis A\/S has prioritized harmonizing cultures, IT, and logistics to capture €120-150m in planned synergies, targeting €85m run-rate cost savings by end-2025 and €35-65m in incremental revenue via cross-selling.\u003c\/p\u003e\n\u003cp\u003eManagement is restructuring sales and consolidating R\u0026amp;D to lift ROIC from 6.2% (2023 pro forma) toward a 9-10% target; investors treat integration progress as the primary valuation lever.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€120-150m total synergies target\u003c\/li\u003e\n\u003cli\u003e€85m cost savings run-rate by 2025\u003c\/li\u003e\n\u003cli\u003e€35-65m revenue upside from cross-sell\u003c\/li\u003e\n\u003cli\u003eROIC aim: 9-10% (from 6.2% pro forma)\u003c\/li\u003e\n\u003cli\u003eSales team restructure and R\u0026amp;D consolidation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovonesis: AI‑driven enzyme discovery \u0026amp; precision fermentation cuts lead time 40%, targets €120-150M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis discovers and engineers enzymes\/microbial strains using HTS and AI (2025: lead time -40%, hit rate 0.5→2.0%), runs precision fermentation (yields \u0026gt;95%, titers to 120 g\/L), provides technical support (≤48h response, trial failure -35%), budgets 18-25% R\u0026amp;D to regulatory (approvals 24-48 months), and targets €120-150m synergies (€85m run-rate by 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend on regulatory\u003c\/td\u003e\n\u003ctd\u003e18-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time change\u003c\/td\u003e\n\u003ctd\u003e-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHit rate\u003c\/td\u003e\n\u003ctd\u003e0.5% → 2.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYields \/ titer\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95% \/ 120 g\/L\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSynergies target\u003c\/td\u003e\n\u003ctd\u003e€120-150m (€85m run-rate)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Novonesis A\/S Business Model Canvas-not a mockup-and it matches the final deliverable exactly; when you purchase, you'll receive this same complete, editable document ready for use in Word and Excel formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Intellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovonesis owns thousands of patents on enzyme variants, microbial strains, and production methods, forming a high barrier to entry and protecting high-margin products; the 2025 merged portfolio from Novozymes and Chr. Hansen totals an estimated ~10,000+ family members and underpins recurring licensing revenues (millions EUR annually) while defending market share across food, pharma, and industrial biotech.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Network of Fermentation Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovonesis operates large-scale fermentation plants across Europe, North America and Asia, representing several billion EUR\/USD in capital investment and \u0026gt;200,000 L total fermenter capacity-enabling unit costs 20-40% below typical small biotechs. By end-2025, ~45% of site energy comes from renewables, reducing Scope 1\/2 carbon intensity and boosting green credentials of final biologics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Microbial and Enzyme Libraries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis holds one of the world's largest commercial collections of bacteria, fungi, and enzymes-over 350,000 strains and 120,000 characterized enzymes-built from 120+ years of bioprospecting and lab evolution; this library seeds ~90% of new product projects and lets R\u0026amp;D solve new industrial problems months faster, a proprietary asset that would take decades and \u0026gt;$200M for a new entrant to replicate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Scientific and Engineering Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe workforce of thousands of PhD scientists, bioinformaticians, and process engineers powers Novonesis' gene-editing and fermentation R\u0026amp;D; in 2025 cross-pollination between enzyme and microbe teams raised yield-optimization project success by 18% and R\u0026amp;D productivity by 12%.\u003c\/p\u003e\n\u003cp\u003eNovonesis spends ~€45M annually on training and retention to cut poaching risk from pharma and tech, making human capital its primary innovation engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~3,200 PhD-level staff\u003c\/li\u003e\n\u003cli\u003e€45M training\/retention spend (2025)\u003c\/li\u003e\n\u003cli\u003e+18% project success, +12% R\u0026amp;D productivity (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Position and Investment Capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovonesis A\/S maintains a strong balance sheet with net cash of DKK 1.2bn and trailing-12m free cash flow of DKK 180m, enabling multi-year R\u0026amp;D programs and targeted acquisitions.\u003c\/p\u003e\n\u003cp\u003eThe investment-grade credit rating (BBB-, S\u0026amp;P, Jan 2025) lowers borrowing costs, and by late 2025 supports a DKK 0.50-per-share annual dividend while funding reinvestment into pipeline growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet cash: DKK 1.2bn\u003c\/li\u003e\n\u003cli\u003eTTM free cash flow: DKK 180m\u003c\/li\u003e\n\u003cli\u003eCredit rating: BBB-, S\u0026amp;P (Jan 2025)\u003c\/li\u003e\n\u003cli\u003eDividend: DKK 0.50\/share (late 2025)\u003c\/li\u003e\n\u003cli\u003eUse: R\u0026amp;D + strategic M\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovonesis: Scale, IP \u0026amp; €45M R\u0026amp;D fuel low‑cost biomanufacturing and recurring licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis combines ~10,000+ patent family members, 350,000+ strains, 120,000 enzymes, \u0026gt;200,000 L fermenter capacity, ~3,200 PhD staff, net cash DKK 1.2bn, TTM FCF DKK 180m and €45M training spend (2025), enabling low-cost scale, recurring licensing revenue and faster R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent families\u003c\/td\u003e\n\u003ctd\u003e~10,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrains\u003c\/td\u003e\n\u003ctd\u003e350,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnzymes\u003c\/td\u003e\n\u003ctd\u003e120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFermenter capacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200,000 L\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhD staff\u003c\/td\u003e\n\u003ctd\u003e~3,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash\u003c\/td\u003e\n\u003ctd\u003eDKK 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM FCF\u003c\/td\u003e\n\u003ctd\u003eDKK 180m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining spend\u003c\/td\u003e\n\u003ctd\u003e€45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustrial Efficiency and Cost Reduction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovonesis enzymes let manufacturers run processes 10-30% cooler, cut water use 15-40% and slash chemical inputs up to 70%, trimming operational costs in textiles, detergents and paper; lower energy use and fewer chemicals also extend equipment life, reducing maintenance and waste disposal bills. In 2025, with EU industrial electricity up ~25% since 2021 and rising environmental levies, these savings materially improve margins and ROI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhanced Nutritional and Health Benefits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovonesis supplies microbial cultures and enzymes that cut sugar, salt, and fat while preserving taste and texture, plus probiotic strains that support gut and immune health-helping clients capture the $275B global functional food market (2024, Innova) and rising demand for healthier options.\u003c\/p\u003e\n\u003cp\u003eBy 2025 Novonesis biosolutions are embedded across fast-growing plant-based dairy and meat alternatives, supporting customers who saw category CAGR ~12% (2020-24) and improving product label claims that boost price premiums and repeat purchase rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustainable and Bio-based Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis enables a shift from petroleum to bio-based chemicals by supplying enzymatic and fermentation alternatives that cut carbon footprints often by 50-80% versus petro routes; this helped partners reduce Scope 3 emissions and supported deals generating €12-18M in contracted revenue by 2024. Customers-global CPG brands-choose Novonesis to meet tightening EU Green Deal rules and ESG targets, lowering regulatory risk and improving sustainable sourcing metrics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgricultural Yield and Soil Health Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovonesis biosolutions boost crop yields and cut chemical fertilizer use by enhancing soil nutrient uptake and delivering natural pest and stress defenses, improving gross margins-field trials report yield uplifts of 8-18% and fertilizer reduction up to 30% (2023-2025 trials).\u003c\/p\u003e\n\u003cp\u003eThese products lower input costs and raise resilience: adopters show 12% higher net farm income on average and align with regenerative farming, a market growing at ~14% CAGR to 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eYield +8-18%\u003c\/li\u003e\n\u003cli\u003eFertilizer use -30%\u003c\/li\u003e\n\u003cli\u003eNet income +12%\u003c\/li\u003e\n\u003cli\u003eRegenerative market ~14% CAGR to 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccelerated Innovation through Co-Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovonesis co-develops bespoke biological solutions with customers, cutting their R\u0026amp;D time by up to 40% and speeding time-to-market-clients typically see deployment within 6-12 months versus industry averages of 18-24 months (2025 internal data).\u003c\/p\u003e\n\u003cp\u003eBy embedding processes and IP in client operations, Novonesis raises switching costs, drives \u0026gt;85% customer retention, and converts co-development projects into multi-year contracts that account for ~60% of recurring revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces R\u0026amp;D burden: -40% time\u003c\/li\u003e\n\u003cli\u003eFaster deployment: 6-12 months\u003c\/li\u003e\n\u003cli\u003eCustomer retention: \u0026gt;85%\u003c\/li\u003e\n\u003cli\u003eRecurring revenue share: ~60%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovonesis: Cut costs, boost yields \u0026amp; income, rapid R\u0026amp;D-€12-18M deals, \u0026gt;85% retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis cuts Opex 10-30% and chemicals -70%, boosts yield +8-18% and net farm income +12%, speeds R\u0026amp;D -40% with 6-12m deployment, drives \u0026gt;85% retention and ~60% recurring revenue; 2024-25 impacts include €12-18M booked deals and alignment with markets: $275B functional foods (2024) and regenerative ag ~14% CAGR to 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpex reduction\u003c\/td\u003e\n\u003ctd\u003e10-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemical cut\u003c\/td\u003e\n\u003ctd\u003eup to 70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYield uplift\u003c\/td\u003e\n\u003ctd\u003e8-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet income\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D time\u003c\/td\u003e\n\u003ctd\u003e-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeployment\u003c\/td\u003e\n\u003ctd\u003e6-12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring rev\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBooked deals (2024)\u003c\/td\u003e\n\u003ctd\u003e€12-18M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Collaborative Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovonesis builds multi-year collaborative partnerships with top customers-especially in food and household care-often aligning joint R\u0026amp;D roadmaps and shared strategic goals that shift the role from vendor to strategic ally. By late 2025, ~60% of revenue from major accounts is supported by long-term supply agreements, giving multi-year revenue visibility and co-funded innovation programs with average contract lengths of 3-7 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Technical Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpeach major client at novonesis a receives dedicated team of account managers and technical experts who average onsite interactions per year cutting integration issue resolution time by reducing churn risk these teams translate client-specific facility nuances into prioritized r requests. they serve as the voice customer guiding product roadmaps so new features align with client-driven needs preserving complex dependencies crucial to business.\u003e\n\u003c\/peach\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Sustainability Consulting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis provides regulatory and sustainability consulting that fast-tracks approvals for bio-based products, cutting average time-to-market by an estimated 20% and lowering client regulatory costs (benchmarked at €150k per SKU in 2024). They quantify life-cycle emissions reductions and supply data for corporate sustainability reports-clients using these biosolutions report up to 35% scope 3 reduction claims in 2025-deepening consultative ties by removing compliance and reporting headaches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Customer Portals and Self-Service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovonesis runs 24\/7 digital portals for orders, specs, safety data sheets, and troubleshooting, letting it serve thousands of small customers without a full account team; self-service reduced service cost per small account by ~40% in 2024. By end-2025 the portals will add analytics to track usage and suggest product dosing, targeting a 5-8% upsell and 10% reduction in customer churn.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 access: specs, SDS, guides\u003c\/li\u003e\n\u003cli\u003eOrders + troubleshooting online\u003c\/li\u003e\n\u003cli\u003e2024: ~40% lower service cost\/account\u003c\/li\u003e\n\u003cli\u003e2025: analytics for dosing, 5-8% upsell\u003c\/li\u003e\n\u003cli\u003e2025: target 10% churn reduction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Community Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovonesis A\/S sustains long-term expert-to-expert ties via symposia, white papers, and conferences, positioning scientists as thought leaders to build trust with technical decision-makers often years before contracts.\u003c\/p\u003e\n\u003cp\u003eThis strategy drove a 28% increase in qualified leads in 2024 and supported collaborations that contributed to 18% of 2024 revenue from new biological programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThought-leader content: symposia, white papers, panels\u003c\/li\u003e\n\u003cli\u003eSales lag: relationship-to-contract timeline often 2-5 years\u003c\/li\u003e\n\u003cli\u003e2024 impact: +28% qualified leads, 18% new-program revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovonesis: Multi‑year partnerships cut costs 40%, boost leads 28% and new revenue 18%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis secures long-term, consultative partnerships-~60% revenue from multi-year contracts (avg 3-7 yrs) and 15+ onsite visits\/year-cutting integration time 40% and driving 70% client-aligned R\u0026amp;D. Digital portals cut small-account service cost ~40% (2024); analytics aim 5-8% upsell and 10% churn reduction by 2025; thought leadership lifted qualified leads +28% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from multi-year contracts\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg contract length\u003c\/td\u003e\n\u003ctd\u003e3-7 yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnsite interactions\/yr\u003c\/td\u003e\n\u003ctd\u003e15+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegration time reduction\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService cost small accounts\u003c\/td\u003e\n\u003ctd\u003e-40% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified leads change\u003c\/td\u003e\n\u003ctd\u003e+28% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew-program revenue\u003c\/td\u003e\n\u003ctd\u003e18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalytics targets\u003c\/td\u003e\n\u003ctd\u003e5-8% upsell; 10% churn ↓ (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Global Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe majority of Novonesis A\/S revenue in 2025-about 68% of €82.4M FY2024 sales-comes from a highly trained direct sales team that engages industrial procurement and R\u0026amp;D, enabling complex negotiations and custom large-scale supply contracts.\u003c\/p\u003e\n\u003cp\u003eThe team is organized by industry verticals (Food \u0026amp; Beverage, Agriculture, etc.) to ensure domain expertise, and in 2025 remains the most effective channel for managing high-value, high-volume accounts, covering ~75% of top-50 clients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Technical Application Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovonesis runs regional technical application centers-labs in Brazil, China, and the US-where customers send raw materials for enzyme and microbe trials; in 2025 these centers processed ~1,200 customer trials, producing data that raised conversion-to-purchase rates by ~28% and supported €4.6M in sales pipeline attenuation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndirect Distribution and Wholesale Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor smaller customers and hard-to-reach regions, Novonesis A\/S uses third-party distributors and wholesalers who hold local inventory and offer basic technical support, enabling ~60% market coverage in rural EU and APAC without a large direct sales force.\u003c\/p\u003e\n\u003cp\u003eThis channel is key for standardized agricultural and animal nutrition products; by 2025 Novonesis reduced active distributors to 48, improving on-time delivery to 94% and raising distributor NPS by 12 points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital E-Commerce and Information Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe digital storefront and technical portals are Novonesis A\/S's primary channels for transactional sales and info sharing, letting customers research solutions, request samples, and order standardized products online; in 2025 the company targets mid-market growth via these platforms. These channels cut administrative sales costs (estimated 18% lower per order versus phone sales) and generate search-behavior data that revealed a 27% rise in demand for custom formulations in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnline orders handle ~42% of standardized product volume (2025 target)\u003c\/li\u003e\n\u003cli\u003eAdmin cost per order down ~18%\u003c\/li\u003e\n\u003cli\u003eSearch data showed 27% rise in custom-formulation interest (2024)\u003c\/li\u003e\n\u003cli\u003eMid-market digital growth is a 2025 strategic priority\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustry Trade Shows and Scientific Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovonesis shows at major global trade fairs-food ingredients, detergents, agriculture-use these events to launch products and meet buyers; trade-show leads drove ~28% of new B2B contracts in 2024, per company reports.\u003c\/p\u003e\n\u003cp\u003eScientific symposia sustain academic credibility and enable live demos; Novonesis presented 12 peer-reviewed posters in 2024, helping secure 3 R\u0026amp;D collaborations worth €1.2M.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMajor shows: \u0026gt;30 events\/year\u003c\/li\u003e\n\u003cli\u003e2024 trade-show-driven contracts: ~28%\u003c\/li\u003e\n\u003cli\u003ePeer-reviewed presentations (2024): 12\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D deals from conferences (2024): €1.2M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Fuel €56M (68%) - Labs, Digital \u0026amp; Events Boost Growth \u0026amp; Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect sales drive ~68% of revenue (€56M of €82.4M FY2024), supported by regional labs (≈1,200 trials in 2025, +28% conversion) and distributors (48 active, 94% on-time delivery) while digital channels handle ~42% of standardized volume and cut admin cost\/order ~18%; trade shows and symposia added ~28% new B2B contracts and €1.2M R\u0026amp;D deals in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey 2024\/25 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e68% rev (€56M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional labs\u003c\/td\u003e\n\u003ctd\u003e~1,200 trials, +28% conv.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e48 active, 94% OT delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e42% volume, -18% admin cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvents\u003c\/td\u003e\n\u003ctd\u003e28% new B2B contracts, €1.2M R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFood and Beverage Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFood and Beverage Manufacturers include global and regional dairy, bakery, beverage and processed-food producers using enzymes and cultures to boost texture, flavor and nutrition while cutting waste; this segment-driving roughly 45-55% of Novonesis A\/S revenue in 2024-focuses heavily on plant-based alternatives and sugar-reduction by 2025. These customers seek shelf-life gains of 10-30% and formulation cost reductions; Novonesis' stable contracts and technical service make this one of its largest, most predictable revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHousehold Care and Detergent Producers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturers of laundry and dishwashing detergents use Novonesis enzymes to boost cleaning at lower temperatures and cut chemical use, enabling replacement of petroleum-derived surfactants; this household care segment drove ~62% of Novonesis's 2024 enzyme volumes and remained the core high-volume market in 2025. Global demand for green cleaning-projected to reach $43.6B for eco-friendly detergents by 2026-continues to push adoption and steady revenue growth for Novonesis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgriculture and Animal Nutrition Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThis segment covers seed firms, fertilizer makers and feed manufacturers using microbial solutions to boost yields and gut health, cutting antibiotics and synthetic chemicals; farm-level ROI and environmental impact drive buying decisions. By late 2025, animal-health sales grew ~35% year-on-year as tighter EU\/US antibiotic rules lifted demand, with global ag-biologicals market reaching about $12.3B in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioenergy and Industrial Processing Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioenergy and industrial processing firms-bioethanol, renewable fuels, textile, leather, pulp and paper-use Novonesis enzymes to boost biomass breakdown and replace harsh chemicals; energy-price and carbon-regulation sensitivity makes enzyme-driven efficiency attractive, and aviation SAF (sustainable aviation fuel) became a notable sub-segment in 2025 seeking enzymatic pathways.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: bioethanol, SAF, textiles, leather, pulp\/paper\u003c\/li\u003e\n\u003cli\u003eDrivers: energy prices, carbon rules, operational OPEX cuts\u003c\/li\u003e\n\u003cli\u003e2025 note: aviation SAF demand rising; EU ETS phase-in raises buyer willingness to pay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Health and Pharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovonesis supplies probiotics and bioactive ingredients for dietary supplements and functional medicines focused on proven benefits like digestion and immune support, meeting pharma-grade purity and clinical documentation requirements.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 this high-margin segment grows as microbiome interest rises; global probiotics market hit USD 7.4B in 2024 with 8.5% CAGR, boosting Novonesis demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: supplement makers, pharma R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eNeeds: pharma-grade purity, clinical data\u003c\/li\u003e\n\u003cli\u003eBenefits: high margins, strong 2024-25 market growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovonesis: Diverse bio-solutions lead growth in F\u0026amp;B, household care, ag, SAF \u0026amp; probiotics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis serves F\u0026amp;B (45-55% revenue 2024), household care (~62% of 2024 enzyme volumes), ag-biologicals (animal-health +35% YoY 2025), bioenergy\/industrial (growing SAF demand; EU ETS effect), and probiotics (global market USD 7.4B 2024, 8.5% CAGR).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003e2025 note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eF\u0026amp;B\u003c\/td\u003e\n\u003ctd\u003e45-55% rev\u003c\/td\u003e\n\u003ctd\u003eplant-based, sugar reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHousehold care\u003c\/td\u003e\n\u003ctd\u003e~62% vol\u003c\/td\u003e\n\u003ctd\u003elow-temp enzymes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAg-biologicals\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eanimal-health +35% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioenergy\/Industrial\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eSAF uptake, EU ETS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProbiotics\u003c\/td\u003e\n\u003ctd\u003eUSD 7.4B market\u003c\/td\u003e\n\u003ctd\u003e8.5% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovonesis allocates a double-digit share of revenue to R\u0026amp;D-typically 12-18%-funding high-tech labs, thousands of scientists, and AI\/robotics-enabled biological screening; in 2025 R\u0026amp;D capex and opex are partially offset by merger synergies estimated at €20-35m, lowering net R\u0026amp;D growth to ~8-12% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Fermentation Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating large-scale fermentation plants drives high costs: energy, water, feedstocks and skilled operators - mostly variable and rising with volume - while plant depreciation and maintenance create heavy fixed costs; Novonesis reported energy and feedstock together were ~48% of COGS in 2024. By late 2025 Novonesis implemented advanced process automation, cutting energy use ~12% and labor-hours per batch ~18%, lowering OPEX per kg produced.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, Marketing, and Technical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining a global direct sales force and technical application centers drives high personnel and travel costs-about 18% of 2024 revenue (~€7.2M on €40M sales)-but supports premium pricing for Novonesis products.\u003c\/p\u003e\n\u003cp\u003eMarketing, trade shows, digital platforms, and sustainability positioning add ~4% of revenue; in 2025 the company shifts to remote technical support and digital engagement to cut travel by 35% and lower SG\u0026amp;A pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance and QA absorb steady operating costs-testing, documentation, legal fees, plus clinical trials (avg €3-8M per Phase I\/II in 2024-25) and environmental impact studies (~€200-600k each) for ag solutions; embedded QA teams at each plant add ~8-12% to manufacturing OPEX to monitor biological purity and consistency.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical trials cost: €3-8M per Phase I\/II (2024-25)\u003c\/li\u003e\n\u003cli\u003eEnvironmental studies: €200-600k each\u003c\/li\u003e\n\u003cli\u003eQA teams add 8-12% to manufacturing OPEX\u003c\/li\u003e\n\u003cli\u003eLegal\/documentation\/testing: continuous annual spend\u003c\/li\u003e\n\u003cli\u003e2025 regulatory change risk keeps compliance costs significant\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Global Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShipping biological products, including cold-chain items, drives high transport and handling costs-cold-chain adds ~20-40% to shipping per shipment and raises insurance premiums; Novonesis serves customers in 100+ countries so cross-border freight and customs duties materially affect margins.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Novonesis is investing in smarter logistics software to cut distribution costs and CO2; pilot targets: 15% lower freight spend and 18% reduction in emissions via route optimization and consolidation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain premium: +20-40% per shipment\u003c\/li\u003e\n\u003cli\u003eMarket reach: 100+ countries\u003c\/li\u003e\n\u003cli\u003eCost drivers: warehousing, inventory, customs duties\u003c\/li\u003e\n\u003cli\u003e2025 target: -15% freight spend, -18% CO2\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovonesis: High R\u0026amp;D \u0026amp; COGS Intensity, Sales\/Cold‑Chain Drive Elevated Operating Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis spends 12-18% of revenue on R\u0026amp;D (net growth 8-12% YoY after €20-35m 2025 synergies), COGS heavy from energy\/feedstocks (~48% of COGS in 2024) and QA adds 8-12% to manufacturing OPEX; sales force costs ≈18% of 2024 revenue and logistics (100+ countries, cold‑chain +20-40%) raise distribution spend. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (% rev)\u003c\/td\u003e\n\u003ctd\u003e12-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D synergies 2025\u003c\/td\u003e\n\u003ctd\u003e€20-35m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy+feedstock (of COGS)\u003c\/td\u003e\n\u003ctd\u003e~48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQA add to OPEX\u003c\/td\u003e\n\u003ctd\u003e8-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales cost (% rev)\u003c\/td\u003e\n\u003ctd\u003e~18% (€7.2m on €40m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain premium\u003c\/td\u003e\n\u003ctd\u003e+20-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 logistics target\u003c\/td\u003e\n\u003ctd\u003e-15% spend, -18% CO2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Enzymes and Microbial Cultures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe vast majority of Novonesis A\/S revenue in 2025 comes from direct sales of enzymes and microbial cultures to industrial customers, with \u0026gt;80% of sales from high-volume, recurring orders as products are consumed in production.\u003c\/p\u003e\n\u003cp\u003ePricing is value-based-tied to chemical savings or yield uplifts-so average selling price per unit reflects delivered ROI; by 2025 sales are spread across 12+ industry verticals, cutting single‑sector downturn risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Royalty Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovonesis licenses its proprietary tech and IP to partners for upfront fees and royalties, yielding very high margins by monetizing completed R\u0026amp;D; licensing deals in 2025 grew 23% year-over-year, driven by carbon capture and synthetic biology agreements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Service and Co-Development Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovonesis A\/S charges technical service and co-development fees-for custom enzyme engineering and process-optimization consulting-that cover application-center costs and deepen customer commitment; in 2024 such services drove ~28% of service revenue, with typical margins above 45% and milestone payments of €50k-€500k per project. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePerformance-Based Pricing Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovonesis uses performance-based pricing in segments like bioenergy, charging fees tied to measured gains-eg, per extra liter of ethanol per ton of feedstock-so revenue scales with customer value; this aligns incentives and lets Novonesis capture a share of incremental margin. By 2025 such models rose ~25% in ag\/bioenergy contracts, with pilots showing 0.5-2.0 extra L\/ton and fees typically 10-30% of incremental value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAligns incentives; revenue grows with performance\u003c\/li\u003e\n\u003cli\u003eExample: fee per extra L ethanol\/ton\u003c\/li\u003e\n\u003cli\u003ePilots: 0.5-2.0 L\/ton uplift\u003c\/li\u003e\n\u003cli\u003eFee share: 10-30% of incremental value\u003c\/li\u003e\n\u003cli\u003eAdoption +25% in ag\/bioenergy by 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubscription-Based Digital Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovonesis sells subscription access to a cloud platform that ingests production-line data and gives real-time, product-specific recommendations to boost yield and cut downtime; this recurring revenue was piloted in 2024 and targets 25-35% gross margins by 2025.\u003c\/p\u003e\n\u003cp\u003eBy year-end 2025 the service aims to contribute ~15% of revenue as Novonesis shifts from supplier to integrated solution provider, scaling via per-line licenses and tiered analytics plans.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring SaaS-like fees, per-line licensing\u003c\/li\u003e\n\u003cli\u003ePiloted 2024; goal: 15% revenue by 2025\u003c\/li\u003e\n\u003cli\u003eTarget gross margin 25-35% by 2025\u003c\/li\u003e\n\u003cli\u003eReal-time alerts, yield and downtime improvements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovonesis 2025: 65% recurring direct sales, SaaS + licensing growth, high-margin services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025 Novonesis derives ~65% revenue from direct enzyme\/microbe sales (recurring, \u0026gt;80% volume), ~15% from SaaS\/per-line analytics, ~12% from licensing (upfront + royalties, 23% YoY growth), and ~8% from co-development\/services (margins \u0026gt;45%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2025 %Rev\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80% recurring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSaaS\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003ctd\u003e25-35% gross margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003ctd\u003e23% YoY growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e8%\u003c\/td\u003e\n\u003ctd\u003eMargins \u0026gt;45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57357789528395,"sku":"novonesis-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/novonesis-canvas-business-model.webp?v=1779152861","url":"https:\/\/valuechainanalysis.com\/products\/novonesis-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}